Study: NCT02153112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (15/50)
Description: Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution